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The interest in vitamin D continues unabated with thousands of publications contributing to a vast 
and growing literature each year. It is widely recognized that the vitamin D receptor (VDR) and the 
enzymes that metabolize vitamin D are found in many cells, not just those involved with calcium and 
phosphate homeostasis. In this mini review I have focused primarily on recent studies that provide 
new insights into vitamin D metabolism, mechanisms of action, and clinical applications. In partic-
ular, I examine how mutations in vitamin D metabolizing enzymes—and new information on their 
regulation—links vitamin D metabolism into areas such as metabolism and diseases outside that of 
the musculoskeletal system. New information regarding the mechanisms governing the function of 
the VDR elucidates how this molecule can be so multifunctional in a cell-specific fashion. Clinically, 
the difficulty in determining vitamin D sufficiency for all groups is addressed, including a discussion 
of whether the standard measure of vitamin D sufficiency, total 25OHD (25 hydroxyvitamin) levels, 
may not be the best measure—at least by itself. Finally, several recent large clinical trials exploring 
the role of vitamin D supplementation in nonskeletal diseases are briefly reviewed, with an eye to-
ward what questions they answered and what new questions they raised.
© Endocrine Society 2020.
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License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, 
distribution, and reproduction in any medium, provided the original work is properly cited.
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1. Introduction
If one enters the term “vitamin D” into the PubMed search engine, looking for articles 
published on this subject over the past 5 years, one finds 21 545 such publications, with 
no evidence of a decline. Clearly vitamin D remains a popular subject of study. As such, 
no review can do justice to the many studies that contribute to the field, and this review 
is no exception. This review will reflect my own bias as to what I find new and exciting, 
acknowledging that it will not be inclusive of the many advances in this field over the past 
few years. What this review will cover is our changing perceptions of vitamin D metabolism 
based on the discovery of mutations in key enzymes affecting such metabolism as well as 
new insights into their regulation, mechanisms of action—including new information on 
how the VDR works in collaboration with other transcription factors and coregulators in dif-
ferent cellular contexts—changing concepts in how vitamin D sufficiency should be defined 
and measured, and, finally, an overall view of what recent large clinical trials are or are not 
telling us about who should take vitamin D supplements and in what doses and schedules.
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2. Vitamin D Metabolism
As is well known, vitamin D is produced in the skin from 7-dehydrocholesterol (7-DHC), 
hydroxylated first in the liver (and other tissues) to 25 hydroxyvitamin (25OHD), and then 
in the kidney (and other tissues) to 1,25 dihydroxyvitamin D (1,25(OH)2D), with subsequent 
catabolism of both 25OHD and 1,25(OH)2D to their 24 (and 23) hydroxy forms, 24,25(OH)2D 
and 1,24,25(OH)3D (or 1,23,25(OH)3D). However, what is new are insights gained into the 
regulation of these steps, including some surprises about the enzymes involved, which we 
will now cover.
A.  7-Dehydrocholesterol Reductase (DHCR7)
Although the production of vitamin D from 7-DHC under the influence of sunlight (UVB) 
is a nonenzymatic step, the production of 7-DHC is not. Its synthesis in the skin is a step 
in the Kandutsch-Russell pathway. DHCR7 converts 7-DHC to cholesterol, so its activity 
dictates how much 7-DHC is available for vitamin D production [1]. This enzyme is found 
in a number of tissues other than the skin, including the brain, muscle, and heart [2]. 
Inactivating mutations of DHCR7 result in the Smith-Lemli-Opitz syndrome, a develop-
mental disorder [3, 4]. These patients suffer primarily from the consequences of too little 
cholesterol, steroids, or bile acids, but they appear to be more sensitive to UVB light, and 
may present with higher serum 25OHD concentrations than normal subjects [5]. On the 
other hand, cats and dogs have increased expression of DHCR7, limiting the amount of 
7-DHC in their skin and so limiting their capacity to make vitamin D [6]. In humans, 
polymorphisms in DHCR7 have been associated with either reduced [7, 8] or increased 
[9] 25OHD levels. The regulation of DHCR7 is incompletely understood. Cholesterol and 
vitamin D (but not 1,25(OH)2D) increase proteasomal degradation of DHCR7, leading to 
increased vitamin D production [10]. AMPK, a key sensor and regulator of cellular energy 
homeostasis and protein kinase A are portent inhibitors of DHCR7, whereas CaMKII has a 
lower inhibitory effect [1, 11].
B.  25-Hydroxylases
The liver is the major if not sole source of 25OHD production from vitamin D. Numerous 
enzymes within both mitochondria and microsomes were found to have 25-hydroxylase 
activity. Initial studies suggested that CYP27A1, a mitochondrial enzyme with substan-
tial homology to both CYP27B1 and CYP24A1 (the 1α and 24-hydroxylases, respectively), 
was the major 25-hydroxylase. But patients with inactivating mutations in this enzyme 
develop cerebrotendinous xanthomatosis with abnormal bile and cholesterol metabolism, 
but not rickets [12]. Thus, the major role of CYP27A1 is to convert cholesterol to cholic 
acid and chenodeoxycholic acids such that mutations in CYP27A1 lead to reduced bile acid 
production and increased cholestanol that accumulates in the brain, causing progressive 
neurologic dysfunction [13] Moreover, in mouse studies, deletion of the Cyp27a1 failed to 
lower blood levels of 25OHD (deletion actually led to increased levels) [14]. Current data sup-
port CYP2R1 as the major 25-hydroxylase at least in the liver (and testes), where it resides 
in the microsomal fraction. CYP2R1 25-hydroxylates both D2 and D3 with comparable ki-
netics, unlike CYP27A1. When deleted from mice, blood levels of 25OHD fall over 50%, but 
not to zero [14], with little impact on blood levels of calcium and phosphate [14], suggesting 
compensation by other enzymes with 25-hydroxylase activity. Five functional mutations in 
CYP2R1 have been described so far. A Nigerian with severe bone disease and biochemical 
evidence of rickets including a low 25OHD but normal 1,25(OH)2D was discovered to have a 
leu99pro mutation in CYP2R1, the first mutation identified [15]. When tested in vitro this 
mutation was shown to reduce 25-hydroxylase activity [15]. Additional mutations include 
K242N, found in a compound heterozygote with CYP2R1 deficiency and familial rickets 
[16], compound heterozygote mutations involving a splice site (367 + 1,G to A) and an insert 
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(768,iT) [17] in an Arabian family, and a deletion (gly42_leu46 with an inserted arg) in a 
French family [18]. Although these mutations resulted in little or no 25-hydroxyase activity 
in vitro, the subjects maintain normal or even high 1,25(OH)2D levels, and in some cases 
respond to both vitamin D and 1αOHD with further increases in 1,25(OH)2D [16, 18]. As 
adults they tend to lose their need for vitamin D supplementation [18]. Such data suggest 
that as in the mouse, CYP2R1 is not the only enzyme with 25-hydroxylase activity; enzymes 
that may be upregulated to compensate when CYP2R1 activity is blunted.
CYP3A4, the major drug metabolizing enzyme preferentially located in the liver and in-
testine, may be one of these compensating enzymes, as it has 25-hydroxylase activity [19]. 
Complicating the story, however, is that CYP3A also degrades both 25OHD and 1,25(OH)2D, 
hydroxylating them in the 23 and 24 positions like CYP24A1 (to be discussed later) [20]. 
Moreover, an activating mutation in CYP3A has recently been reported that increases 
1,25(OH)2D and likely 25OHD catabolism, resulting in decreases in these metabolite levels 
and rickets [21].
Previously, it had been thought that the 25-hydroxylation of vitamin D was primarily 
substrate dependent. However, recent evidence indicates that this is not the case. Roizen 
et al found that the serum concentration of 25OHD, but not vitamin D, was decreased in 
mice fed a high-fat diet to induce obesity compared with normal weight mice [22]. Moreover, 
mRNA and protein levels of CYP2R1 were decreased in these obese mice. The expression of 
other 25-hydroxylases (CYP27A1, CYP3A) or the catabolizing enzyme CYP24A1 was not al-
tered. Aatsinki et al examined the effect of high-fat diet–induced obesity, fasting, and type 2 
diabetes, as well as streptozotocin-induced (type 1) diabetes, on 25OHD levels in mice [23]. 
All these metabolic manipulations decreased the hepatic mRNA and protein concentration 
of CYP2R1. These authors then demonstrated that the decrease in CYP2R1 was mediated 
by PPARγ-coactivator-1α (PGC1α), a key metabolic regulator increased by fasting or dia-
betes. They then showed that the control of CYP2R1 gene expression by PGC1α involved 
another transcriptional regulator, estrogen-related receptor α (ERRα), which also binds to 
other nuclear receptors such as VDR and the glucocorticoid receptor (GR). Consistent with 
this is that dexamethasone, a ligand for GR, also decreased hepatic CYP2R1 mRNA and 
protein concentrations by a mechanism mediated by increased PGC1α. Thus, our concept 
that the low levels of 25OHD in obesity are somehow related to an increased storage of vi-
tamin D in fat needs to be reexamined.
C.  CYP27B1—the 25OHD-1α Hydroxylase
Unlike the 25-hydroxylases, there is only one 25OHD-1α hydroxylase described, CYP27B1. 
This enzyme is found in the mitochondrion along with CYP24A1. The kidney is the main 
source of circulating 1,25(OH)2D, but many tissues, including the epidermis and other ep-
ithelial tissues, bone, placenta, and cells of the immune system, also express CYP27B1, 
producing 1,25(OH)2D likely for paracrine or autocrine uses [24]. Regulation of CYP27B1 in 
these extracellular sites differs from that in the kidney. In the kidney CYP27B1 is regulated 
primarily by parathyroid hormone (PTH), which stimulates, and fibroblast growth factor 23 
(FGF23) as well as 1,25(OH)2D itself, which inhibit, whereas cytokines such as interferon 
gamma (IFNγ), tumor growth factor alpha (TNFα), and transforming growth factor beta1 
(TGFβ1) are the major inducers of CYP27B1 in nonrenal tissues such as keratinocytes 
and macrophages [25, 26]. Dexamethasone, on the other hand is suppressive [27, 28]—at 
least in macrophages. Moreover, in keratinocytes, activation of TLR2, but not TLR4 (by 
LPS), induces CYP27B1 [26]. In peripheral blood mononuclear cells IL-1, IL-2, and IL-15 
also stimulate CYP27B1 activity, whereas IL-4 is suppressive [29, 30]. Thus, the induc-
tion of CYP27B1 in these extrarenal tissues by cytokines and the failure of CYP27B1 in 
these tissues to respond to the increased circulating levels of 1,25(OH)2D and calcium ac-
count for the hypercalcemia often found in granulomatous diseases such as sarcoidosis and 
lymphomas [24, 31]. Although CYP27B1 regulation has been best studied in keratinocytes 
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and macrophages, tissues such as the parathyroid gland, placenta, and bone have their own 
set of regulators [32].
Mutations in CYP27B1 cause a disease known as pseudovitamin D deficiency rickets 
or vitamin D-dependent rickets, type 1A (VDDR1A) [33, 34]. These individuals are 
characterized by normal to high 25OHD levels and low but not always absent 1,25(OH)2D 
levels. A recent study demonstrated that mice with a global deletion of Cyp27b1 are able 
to produce normal levels of 1,25(OH)2D when given large doses of 25OHD, suggesting that 
other 1 hydroxylases may exist, although none have yet been identified [35]. The sequence 
of the gene was subsequently determined [36–39], enabling the mutations causing this di-
sease to be identified [38, 40]. Both the renal and extrarenal CYP27B1 have the same se-
quence, but their differences in regulation occur as a result of differences in tissue-specific 
multicomponent control modules within the regulatory regions of the gene [41]. These 
studies will be further described when the mechanism of action of VDR is addressed.
D.  CYP24A1 and CYP3A—the 25OHD-24 (23) Hydroxylases
These are the catabolic enzymes of vitamin D metabolism, with both 25OHD and 1,25(OH)2D 
as their substrates. In most tissues CYP24A1 is the dominant 24-hydroxylase, but CYP3A4 
likely plays a role in the liver and intestines, where it is highly expressed. CYP3A4 lacks 
the specificity for vitamin D metabolites shown by CYP24A1 [20], but drugs like rifampin 
can increase its expression leading to osteomalacia [42]. Both enzymes have 24-hydroxylase 
and 23-hydroxylase activity, although the relative proportions of 24-hydroxylase and 
23-hydroxylase activity for CYP24A1 is species-specific [43]. Both enzymes are induced by 
1,25(OH)2D, and the induction of CYP3A4 seems to be at least as great as that for CYP24A1 
in the intestine [44]. The 24-hydroxylase pathway terminates with the biologically inac-
tive calcitroic acid, whereas the 23-hydroxylase pathway produces the biologically active 
1,25,26,23 lactone. These multistep reactions are all catalyzed by one enzyme, CYP24A1 
[45]. To label CYP24A1 as a purely catabolic enzyme in vitamin D metabolism is a misnomer. 
1,24,25(OH)3D has a substantial affinity for the VDR, with biological activity approximately 
10% of 1,25(OH)2D. Moreover, a specific receptor for 24,25(OH)2D, Fam57B2, has been 
identified in bone and other tissues such as the skin, and through this receptor 24,25(OH)2D 
was found to be involved in fracture repair [46]. Deletion of Cyp24a1 in mice results in 
marked decreases in bone mineralization comparable to osteomalacia, which is rescued by 
also deleting the VDR, leading the authors to attribute the changes to large increases in 
1,25(OH)2D [47]. Whether this also applies to humans with biallelic mutations, which, as 
noted below, results in hypercalcemia with increased 1,25(OH)2D levels, has so far not been 
reported [48]. Polymorphisms of the CYP24A1 gene are responsible for modest genetic vari-
ability of serum 25OHD (CYP24A1 is one of the 8 genes known so far to result in genetically 
predisposed higher or lower serum 25OHD concentrations). CYP24A1 is under the control 
of 1,25(OH)2D and FGF23 (both stimulatory) and calcium [49]. 5α-dihydrotestosterone, via 
the progesterone receptor, has also been reported to stimulate CYP24A1 [50]. In humans, 
inactivating mutations in CYP24A1 is now recognized as a major cause of idiopathic in-
fantile hypercalcemia (IIH), a syndrome marked by severe hypercalcemia, hypercalciuria, 
and nephrocalcinosis, decreased PTH, low 24,25(OH)2D, and inappropriately normal to 
high 1,25(OH)2D [51]. At this point no skeletal defects have been described. Twenty-one 
missense mutations have recently been reported in the CYP24A1 gene [52]. Although in-
itially identified in children, recent case reports indicate that the diagnosis may not be 
made until adulthood, generally following a condition of increased 1,25(OH)2D production 
like pregnancy [53, 54], although not always [48, 55]. Such adults generally present with 
early onset nephrolithiasis and/or nephrocalcinosis. It is possible that the hypercalcemia in 
some patients with granulomatous diseases or lymphomas may have an underlying defect 
in CYP24A1 activity and its failure to compensate for the increased 1,25(OH)2D production 
in these diseases.
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E.  Cholesterol side chain cleavage enzyme (CYP11A1)
This enzyme is the rate-limiting enzyme in steroid synthesis, but studies from the Slominski 
laboratory [56] demonstrated that CYP11A1 also metabolizes vitamin D3 to 20(OH)D3, with 
subsequent metabolism to additional metabolites that have biologic activity comparable in 
some cases to 1,25(OH)2D3. CYP11A1 is expressed in the skin and cultured keratinocytes 
[57] as well as better known steroid-producing tissues such as the adrenals, ovary, testes, 
and placenta. At this point, little is known about how this enzyme is regulated in the skin 
and elsewhere with respect to its vitamin D metabolizing activity, and its relative impor-
tance in the physiology of vitamin D remains unclear.
3. Mechanisms of Action
The VDR is critical for most of the actions of vitamin D, with 1,25(OH)2D as its major ligand. 
Vitamin D receptor is a transcription factor found in nearly all cells, although to variable 
levels. It is a member of the steroid hormone receptor family. Although initially identified in 
the small intestine, the VDR has subsequently been found in essentially all tissues in which 
it has been sought [58, 59]. Not surprisingly, vitamin D impacts many cellular processes via 
the VDR. In a recent ontology analysis 11 031 putative VDR target genes were identified, 
of which 43% were involved with metabolism, 19% with cell and tissue morphology, 10% 
with cell junction and adhesion, 10% with differentiation and development, 9% with angi-
ogenesis, and 5% with epithelial to mesenchymal transition [60]. Furthermore, VDR can 
regulate various miRNAs and long noncoding RNAs involving the expression of numerous 
proteins directly or indirectly [61–63]. As a result of the appreciation that the VDR is so 
widespread, along with the key vitamin D metabolizing enzymes such as CYP27B1 and 
CYP24A1 [64], interest in understanding the role of vitamin D and the VDR in nonclassic, 
as well as classic, target tissues regulating calcium and phosphate homeostasis has been 
substantial. Although most actions of VDR involve its role as a transcription factor within 
the nucleus [65–67], the VDR has also been shown to have nongenomic actions via its loca-
tion in the membrane [68] and perhaps even in mitochondria [69].
A.  Structure
The human VDR is located in chromosome 12 and is comprised of 9 exons. Exon 2 contains 
the translation start site and the nucleotide sequence encoding the short A/B domain (24 
amino acids), to which transcription factors such as TFIIB bind, and the first zinc finger 
of the DNA binding domain (DBD) (65 amino acids). Exon 3 encodes the second zinc finger 
of the DBD. Exons 4–6 encode the hinge region (143 amino acids). Exons 7–9 encode part 
of the hinge region, the entire ligand binding domain (E/F) (195 amino acids) including 
the AF2 domain, and the extensive 3 prime untranslated regions (UTR). A polymorphism 
(FokI restriction site) is found in the human VDR, changing an ATG to an ACG and shifting 
the translation start site by 3 amino acids, shifting the total length from 427 to 424 amino 
acids. Numerous other polymorphisms have been described in untranslated regions of the 
VDR gene, to which associations with various diseases have been made. Amino acids 49–50 
between the 2 zinc fingers and 102–104 C-terminal to the zinc fingers appear to provide 
the nuclear localization signal [70, 71]. The DBD is comprised of 2 zinc fingers held in a 
tetrahedral configuration by 4 cysteine residues. The first zinc finger directs DNA binding 
in the major groove of the DNA binding site. The second zinc finger provides a dimeriza-
tion interface for its primary partner RXR [72]. The ligand binding domain is comprised 
of 12 α helices (H1-12) [73]. The terminal H12 provides the mobile portion of the mouse-
trap model for binding of 1,25(OH)2D to the VDR in that in the nonliganded VDR H12 is 
open, but with ligand binding H12 moves over the ligand enclosing it in the ligand binding 
pocket [73]. In the closed position H12 along with H3 and H4 provide the interface for 
coactivators such as the steroid receptor coactivator (SRC) and mediator complexes, which 
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bind to H12 via their nuclear box (NR) containing the LxxLL sequence of amino acids (L 
for leucine, X for any amino acid) [74]. The ligand binding pocket is actually quite large 
and accommodates a number of ligands, including lithocholic acid and the 1,25(OH)2D an-
alog with two side chains called gemini [75]. H9 and H10 along with the second zinc finger 
provide the heterodimerization site for RXR [76]. The membrane VDR accepts a different 
configuration of 1,25(OH)2D (6-S cis rather than 6-S trans conformation), leading Mizwicki 
et al [77] to propose an alternative pocket for ligand binding that is not yet confirmed. Amino 
acid residues critical for the structure/function of the VDR have been well demonstrated by 
mutations in the VDR, either in the human or mouse gene (reviewed in [78]).
B.  Regulation
The regulation of VDR expression is cell specific. For example, 1,25(OH)2D autoregulates 
VDR expression in bone cells but not in the intestine [79, 80]. Many factors including 
1,25(OH)2D regulate VDR expression, including growth factors such as FGF, EGF, IGF, 
insulin, as well as parathyroid hormone, glucocorticoids, estrogen, and retinoic acid in 
some cases acting via a variety of transcription factors such as AP-1, SP1, C/EBP, CDX2, 
C/EBPβ, Runx2, cyclic AMP response element binding protein (CREBP), retinoic acid re-
ceptor (RAR), and GR [81]. Similarly, calcium upregulates VDR expression in the para-
thyroid gland, presumably through its calcium sensing receptor [82]. On the other hand, 
SNAIL 1 and 2 (SLUG) down regulate VDR expression in a number of cancer cell lines [83, 
84]. MiRNAs can regulate VDR levels as exemplified by the binding of miR-125b, miR-298, 
and miR-27b to the 3’UTR to decrease VDR levels [85–87]. The VDR promoter may also be 
hypermethylated by various methylases and methyl transferases reducing its expression 
[88].
C.  Genomic Actions
Carlberg [65] reported that the human genome contains over 23 000 VDR binding sites, 
most of which are cell-specific [89]. Their locations varied with duration of ligand exposure, 
and only some were readily identified with a specific gene [90]. Most but not all of these 
binding sites were ligand dependent [91]. Although the DR3 was the most common binding 
sequence, it occurred in only a minority of binding sites, albeit the ones with the highest 
affinity for VDR. No obvious consensus DNA sequences have emerged for most non-DR3 
binding sites. The DR3 refers to a DNA sequence with 2 hexanucleotide half sites separated 
by a 3 nucleotide spacer, with the consensus sequence of the half sites as A/G G G/T T C/G 
A. The VDR binding sites can be thousands of bases away from the transcription start site 
(TSS) of the genes they regulate, and genes generally have multiple VDR binding sites, the 
activity of which may vary in different cells and different species. The likely explanation 
for this variability is that the DNA can be looped to bring the relevant regulatory elements 
adjacent to the TSS. This function is performed by CCCTC binding factors (CTCF), which 
define genomic insulator regions, although not all CTCF sites are involved with insulator 
actions. Genomic loops of hundreds to thousands of bases can be looped into topologically 
associating domains (TADs) organizing the genome into several thousand such domains 
[92]. An informative example of how this might work in different cells is the regulation of 
the RANKL gene (Tnfsf11). This gene is regulated by PTH and 1,25(OH) 2D in osteoblasts 
but by AP-1 factors such as c-fos in activated T-cells. The Pike Laboratory identified 7 VDR 
binding sites in RANKL up to 88kb upstream of the TSS, of which the -75kb site proved 
most active in the mouse gene [93, 94], whereas the proximal site was most active in the 
human gene [95]. However, in activated T-cells, 3 additional sites even further upstream 
of the TSS have been identified as sites of RANKL induction by c-fos [96]. CTCF binding 
sites separate the RANKL gene from adjacent genes, but also separate the VDR binding 
sites in osteoblasts from the more upstream c-fos binding site active in T-cells, potentially 
enabling different looping in these 2 types of cells [66, 96]. A similar example can be found 
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for Cyp27b1. This gene is negatively regulated by its product in the kidney, but not in other 
tissues [97]. Pike et al identified a specific enhancer module that mediates endocrine regu-
lation of the Cyp27b1 gene in the kidney but not in nonrenal cells [41]. They then deleted 
this kidney-specific module regulating Cyp27b1 to create a kidney-specific Cyp27b1 pseudo-
null mouse [98]. Subsequently, they also identified chromatin-based mechanisms involved 
in the differential regulation of Cyp24a1 in kidney and nonrenal target tissues [99]. The 
VDR binding sites are generally situated in a region with other transcription factors that 
may share regulation of that gene, potentially providing cell-specific regulation of the gene. 
For example, the VDR binding region of the RANKL gene contains several CREB sites 
responsible for PTH regulation of this gene [100, 101]. Runx2 and C/EBPβ binding sites 
can frequently be found in the same regions as the VDR binding sites and influence VDR 
activity [102]. Vitamin D receptor binding sites have also been colocalized with C/EBPβ, 
AP-1, CDX2, vTCF4 [103], ras activated Ets transcription factors [104], and YY1 [105, 106]. 
Changes in VDR binding sites, as can occur during differentiation of the cell, can affect the 
binding of these other transcription factors in a similar fashion [107, 108] as may account 
for the ability of 1,25(OH)2D to inhibit the early stages of osteoblast differentiation while 
promoting the later stages [109] or the sequential effects of 1,25(OH)2D on gene expression 
during keratinocyte differentiation [110].
D.  Coregulators and Epigenetic Changes Regulating VDR Function
The sites of active transcription are marked by epigenetic changes in both the gene it-
self and the histones that regulate access of the transcriptional machinery to the gene 
(review in [111]). For example, H3K4me3 (histone 3, in which lysine 4 is triply methyl-
ated) is found in sites of active transcription, whereas H3K9 is associated with silent 
promoter regions. H3K27ac is associated with active enhancers, whereas H3K27me is 
associated with gene suppression. 1,25(OH)2D can increase or decrease the expression of 
these methylases [112]. Sites of epigenetic gene suppression are also generally marked 
by methylation of cytosine in CpG islands (review in [113]) in association with the ep-
igenetic changes in the histones listed above [114]. 1,25(OH)2D regulates these epige-
netic changes by affecting the binding of coregulators to the VDR, whether coactivators 
with histone acetyltransferase activity (HATs) or cosuppressors with histone deacetylase 
activity (HDACs). There are over 250 published coregulators interacting with nuclear 
hormone receptors [115]. The best studied coactivators with respect to the VDR are the 
steroid hormone receptor coactivators (SRC 1–3) [116] and the Mediator complex [117]. 
Phosphorylation of serine 208 in the VDR following dimerization with RXR enhances 
their binding [118, 119]. The SRCs have 3 NR boxes containing the LxxLL motif described 
earlier to which they bind the nuclear hormone receptors [120], but VDR binding is pri-
marily to the 3rd NR box [121]. Med 1, the principal component of the Mediator com-
plex binding to VDR and other nuclear hormone receptors, has 2 NR boxes, the second 
NR box being the one binding to VDR [121]. Steroid coactivator receptors recruit HATs 
to the VDR, in particular CREB binding protein CBP/p300 [122] and CBP/p300 asso-
ciated factor p/CAF [123]. The Med complex does not contain HAT activity but binds 
directly to RNA polymerase II to help form the preinitiation complex along with basal 
transcription factors such as TFIIB and several TAT binding proteins [124]. The peroxi-
some proliferator-activated γ coactivator-1α (PGC-1α) described earlier in relationship to 
Cyp2r1 regulation interacts with VDR to regulate genes involved with muscle develop-
ment and energy metabolism [125]. These coactivators all bind to the AF2 domain (H12). 
NCoA62/SKIP does not bind to the AF2 domain but binds to the VDR/RXR heterodimer 
to increase transcription with SRC but could also coordinate with corepressors NCoR/
SMRT to suppress transcription [126, 127]. The best studied corepressors are the SMRT 
and NCoR complexes [128, 129], as they have HDAC activity. These corepressors bind to 
nuclear hormone receptors via their CoRNR boxes, which are analogous to the NR boxes 
of the SRC family but with a sequence LxxH/IxxxI/L (L for leucine, H for histidine, I for 
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isoleucine) [130]. These corepressors do not bind to the AF2 domain (H12) but to H3-H5 
in the absence of ligands. In the presence of 1,25(OH)2D and the conformational change 
with H12, these corepressors are displaced, enabling the coactivators to bind to their 
sites on H12. Hairless is a corepressor of VDR expressed primarily in the brain and skin 
[131]. It binds to the central region of the LBD of VDR, as do NCoR/SMRT to two ϕxxϕϕ 
hydrophobic sites (ϕ = hydrophobic aa) [132] but also to H12 via its LxxLL motif, which is 
similar to SRC and Med1 [121]. The role of hairless is complex in that it represses ligand-
dependent VDR functions with respect to epidermal differentiation [131] but is required 
for ligand independent VDR regulation of hair follicle cycling [133].
E.  Nongenomic Actions
1,25(OH)2D also exerts rapid effects on cells that involve nongenomic mechanisms. Rapid 
increases in intestinal calcium transport following 1,25(OH)2D administration was the first 
such example, called transcaltachia [134], but similar effects have been seen in a number 
of other cells, including chondrocytes, osteoblasts, keratinocytes, and fibroblasts. Pathways 
involved in these rapid effects of 1,25(OH)2D include phospholipase C (PLC), phospholipase 
A2 (PLA), phosphatidylinositol-3-kinase (PI3K), wnt5a, and p21 ras, opening-up calcium 
and chloride channels with the generation of second messengers such as calcium, cyclic 
AMP, fatty acids, phosphatidylinositol 3,4,5 triphosphate (IP3) activating downstream pro-
tein kinases A and C, src, mitogen-activated protein kinases (MAPK), and calmodulin ki-
nase II (reviews in [135, 136]). Two receptors for 1,25(OH)2D, both in the membrane, have 
been identified as mediating these rapid actions. The first such receptor initially called 
membrane-associated rapid response steroid (MARRS) binding protein [137] also goes by the 
names of thioredoxin-like protein (GRP58), endoplasmic reticulum protein 57/60 (ERp57 or 
60), and protein disulfide isomerase family A, member 3 (Pdia3) [138]. The second receptor 
is the VDR itself, but in its membrane location it is activated by 1,25(OH)2D analogues with 
a different configuration (6-S cis) than those that activate the genomic actions of VDR (6-S 
trans), as mentioned earlier [139, 140]. These receptors can co-localize with caveolin-1 in 
caveolae [141] and may physically interact [142]. Similarly, interaction between the mem-
brane VDR and the nuclear VDR has been suggested. For example, in kidney and intestinal 
cells the rapid activation of ERK 1/2, JNK1/2, PKC, PI3K, and p21ras have all been shown 
to regulate 1,25(OH)2D induction of Cyp24a1 [143–145] by a number of mechanisms, in-
cluding phosphorylation of RXRα and Ets-1. The VDR may alter the actions of other tran-
scription factors in a nongenomic fashion, as exemplified by its interaction with IкB kinase, 
to block NFкB signaling [146]. Similarly, MARRS/ERp57/PIA3 interacts directly with NFкB 
to facilitate the translocation of the complex into the nucleus to promote the differentiation 
of NB4 leukemia cells [147]. Deletion of MARRS/ERp57/PIA3 is embryonic lethal [148], but 
the heterozygote and the chondrocyte-specific deletion of MARRS/ERp57/PIA3 result in an 
enlargement of the growth plate, with an increased hypertrophic zone, increased apoptosis 
of the chondrocytes, and decreased trabecular bone [148, 149]. This phenotype has been 
attributed to increased endoplasmic reticulum (ER) stress due to improper protein folding 
in the ER because of the loss of this protein [149]. These findings disappear following pu-
berty [149]. Thus, the mechanisms of VDR can be quite complex and generally cell specific 
with numerous layers of regulation.
4. Vitamin D Sufficiency
25OHD is the principal measure by which vitamin D sufficiency is currently determined 
for several reasons. First, 25OHD is the vitamin D metabolite in highest concentration in 
the blood, so it is the easiest to measure. Second, nearly all 25OHD is in the blood, unlike 
vitamin D itself, which is stored in tissues such as fat. Third, 25OHD has a half-life in blood 
measured in weeks, unlike hours for 1,25(OH)2D. That said, total 25OHD may not be the 
best measurement of vitamin D status.
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A.  Free Versus Total 25OHD
25OHD, like other vitamin D metabolites, is carried in blood by 2 major proteins, vitamin D 
binding protein (DBP) and albumin. D binding protein binds whereas albumin binds 15% of 
the total 25OHD approximately 0.03% free in normal individuals [150]. Except for tissues 
expressing the megalin/cubilin complex, it is the free fraction that is generally considered to 
enter most cells (the free hormone hypothesis).This is similar to that for the thyroid and ste-
roid hormones [151, 152], which like vitamin D metabolites are transported in blood bound 
to their respective binding proteins. There are a number of drugs and cytokines (dexameth-
asone and IL-6, for example) as well as clinical conditions (eg, pregnancy, liver disease, 
nephrotic syndrome, primary hyperparathyroidism, and acute trauma) that influence the 
circulating levels of DBP, effectively altering the ratio of total to free 25OHD [153, 154]. 
Thus, measuring just the total 25OHD levels would be misleading if in fact it was the free 
concentration to which most cells respond. Therefore, the determination of the free level of 
25OHD might be a better, or at least a complementary, assessment of vitamin D status than 
the total level, although this remains controversial [154, 155].
B.  Assay Concerns
An additional consideration in determining vitamin D sufficiency is the variability among 
assays [156]. Most currently used assays involve antibodies that may differ between 
laboratories in their ability to measure 25OHD2 compared to 25OHD3 or their sensitivity to 
interfering substances [157]. The increasing use of mass spectroscopy coupled with an initial 
chromatographic step (LC/MS/MS) to measure vitamin D metabolites ameliorates many of 
the problems with immunometric assays [157], although this method remains restricted to 
larger clinical and commercial laboratories. Meanwhile, efforts are being made to harmonize 
the data from different laboratories in different countries [158] so that recommendations 
can be based on data comparable from one study to another. The Vitamin D Standardization 
Program (VDSP) was developed in an attempt to rectify this situation [159]. The VDSP 
coordinates the international effort to standardize serum 25OHD measurement to gold 
standard reference assays that have been developed. To this end the National Institute 
of Standards and Technology (NIST) has developed reference methods and materials for 
standardizing the measurements of a number of vitamin D metabolites. Finally, even if the 
problems with the assays are solved, it is not clear that 25OHD levels that are optimal for 
Caucasians are the same as those for Black Africans, Hispanics, or Asians. Not surprisingly, 
therefore, current guidelines vary, and at this point current guidelines must be considered 
a work in progress.
C.  Current Guidelines
The most consistent data, and the data used in establishing recommendations either for 
optimal levels of circulating 25OHD levels or levels of dietary supplements, come from 
studies involving the musculoskeletal system. In the various guidelines provided by dif-
ferent agencies different terms are used, such as the estimated average requirement (EAR), 
which is the median level at which 50% of the population would be sufficient; the required 
daily requirement (RDA), which is the level that meets the needs of 97.5% of the population; 
or terms such as adequate intake (AI), reference nutrient intake (RNI), and recommended 
intake (RI). The recommended levels for dietary intake assume no additional contribution 
from epidermal production of vitamin D.
In an international effort to provide a consistent set of guidelines, 33 nominated experts 
from pediatric endocrinology, pediatrics, nutrition, epidemiology, public health, and health 
economics recently published their consensus recommendations on the prevention and 
management of nutritional rickets [160]. They defined vitamin D sufficiency as 25OHD 
levels above 50 nM (20 ng/ml), insufficiency between 30–50 nM, and deficiency below 30 nM 
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(12 ng/ml). Moreover, they noted that the consequences with respect to the development 
of rickets/osteomalacia were also dependent on calcium intake. They defined calcium suf-
ficiency as > 500 mg/day, insufficiency as 300 –500 mg/day, and deficiency as < 300 mg/
day. Individuals with the combination of insufficient or deficient levels of either calcium or 
vitamin D and deficient levels of the other were most at risk for rickets. Deficiency of vi-
tamin D with a normal calcium intake might lead to biochemical abnormalities but not to 
rickets/osteomalacia, according to their analysis. They recommended 400 IU of vitamin D/
day for infants up to 1 year and followed the Institute of Medicine’s (IOM) (now known as 
the National Academy of Medicine [NAM]) recommendations for older children and adults 
(see below).They further recommended 200 mg calcium/day for infants up to 6 months, and 
260 mg/day from 6–12 months. Recommendations for calcium intake of older children were 
500 mg calcium/day or more. Other than the recommendation of the NAM for adults to 
ingest 700–1300 mg calcium/day [161], most other guidelines are silent with respect to cal-
cium. With respect to vitamin D the NAM recommended 600 IU from years 1–70 and 800 IU 
above age 70. The NAM considered a 25OHD serum level of 50 nM (20 ng/ml) to suffice for 
97.5% of the population [161]. The Endocrine Society guidelines recommend 75 nM (30 ng/
ml), considering levels between 50–75 nM as insufficient and less than 50 nM as deficient 
[162]. Although the Endocrine Society’s recommendations for children and adults are com-
parable to other groups (400 IU/day for infants, 600 IU/day from ages 1–70, 800 IU/day 
for those over 70), the Endocrine Society suggests that doses up to 2000 IU of vitamin D/
day may be necessary to achieve and maintain a serum 25OHD level of 75 nM (30 ng/ml). 
Guidelines from other countries have recently been reviewed [163] and in general are con-
sistent with those described above.
Some guidelines also include upper limits beyond which more vitamin D and/or calcium 
is not recommended. The NAM, for example, recommends that vitamin D intake should 
not exceed 4000 IU/day or a calcium intake above 2000–3000 mg/day (based on age) [161]. 
However, other studies indicate that at least in healthy individuals, doses up to 10 000 IU/
day of vitamin D are not toxic. The upper limits of calcium intake beyond which toxicity 
develops are less clear, as the doses recommended have also been associated with increased 
kidney stones and cardiovascular disease [164].
5. Clinical Applications
As noted above, the guidelines are based primarily on data from studies of the musculoskel-
etal system, both association studies and randomized clinical trials, as summarized in a re-
cent review [165]. Baseline vitamin D and calcium levels appear to be important markers for 
responsiveness. A 400 IU dose of vitamin D sufficed to prevent rickets in a study in Turkey, 
where deficiency was extensive [166]. Other studies in adult populations demonstrated el-
evated PTH levels and reduced bone mineral density at 25OHD levels below 50 nM [167, 
168] and increased osteoid suggestive of osteomalacia in hip fracture patients with 25OHD 
levels below 30 nM [169, 170]. At these levels vitamin D supplementation shows a clear ben-
efit [171]. Vitamin D supplementation works better when used in conjunction with calcium 
[172–174], especially in the elderly and vitamin D deficient. Although not all studies have 
demonstrated protection against fractures, several have when elderly vitamin D deficient 
populations are studied [174, 175], but not when vitamin D sufficient populations are studied 
[176]. Moreover, the amount and administration schedule also matter. Use of very high doses 
of vitamin D (ie, 300 000–500 000 IU given annually) seems to increase fracture risk [177, 
178]. Similar conclusions can be reached for falls. Daily doses of 700–1000 IU of vitamin D 
reduce the risk of falls in the elderly, especially those with vitamin D insufficiency [179, 180], 
but higher doses intermittently administered appear to increase the risk of falling [177, 181]. 
The reduction in falls is likely related to improvement in muscle function, as seen best in the 
most frail with lowest 25OHD levels [182]. With respect to nonmusculoskeletal diseases, al-
though vitamin D supplementation has been associated with reduced overall mortality, most 
diseases that have shown an association with low 25OHD levels, with the exception of upper 
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respiratory illnesses and asthma, have not yet shown consistent benefit with vitamin D sup-
plementation [183, 184]. However, most of these studies have not discriminated between 
participants with sufficient versus insufficient 25OHD levels, so the jury is still out. Two re-
cently published large clinical trials exemplify this point. The VITAL study [185] examined 
the ability of vitamin D, 2000 IU/day, and/or omega 3 fatty acid to reduce the risk of cancer 
and cardiovascular events. This was a very large trial, with 25 871 participants (men over 50, 
women over 55), including a large number of African Americans with a median study dura-
tion of 5.3 years. The median 25OHD level was 31 ng/ml, which is considered vitamin D suf-
ficient even by Endocrine Society guidelines. The primary endpoints of invasive cancer and 
major cardiovascular events showed no significant risk reduction, although in a secondary 
analysis the group with a body mass index (BMI) of less than the median 27.1 taking vitamin 
D had a significant reduction in invasive cancer. This is of interest given that as discussed 
in the section on vitamin D metabolism, this group may have had a higher CYP2R1 level 
and so responded to the vitamin D supplementation with a greater increase in 25OHD. This 
remains to be demonstrated, as post-trial 25OHD levels were not determined. Moreover, it 
was not clear whether individuals with low 25OHD levels at baseline responded better to 
supplementation than those with normal levels of 25OHD. The D2D study [186] evaluated 
the ability of vitamin D, 4000 IU/day, to reduce the risk of developing diabetes mellitus in 
2423 prediabetics over a mean time of 2.5 years. The median baseline 25OHD level in this 
population was 28 ng/ml. Although the hazard ratio in the vitamin D supplemented group 
was 0.88 relative to placebo controls, this was not quite statistically significant (P = 0 = .12), 
although in a post hoc analysis, subjects with baseline 25OHD levels < 12 ng/ml had a sig-
nificant benefit from vitamin D supplementation (HR 0.38). Moreover, like the VITAL study, 
the group of study subjects with BMIs less than 30 also showed a significant reduction in 
progression to diabetes in a subgroup analysis. Therefore, we may expect that future clinical 
trials will focus on nonobese subjects with baseline 25OHD levels in the insufficient range, 
as they may have a greater response to the supplementation.
6. Conclusion
Studies in vitamin D over the past several years have produced a number of new insights 
into vitamin D metabolism, mechanisms of action, and guidance for clinical applications, as 
summarized in Table 1. Mutations in the metabolizing enzymes have helped elucidate the 
Table 1. New Concepts in Vitamin D Metabolism and Function
•  The level of 7-dehydrocholesterol, the substrate for vitamin D production, is controlled by the activity of 
7-dehydrocholesterol reductase, an enzyme in the skin regulated by vitamin D and AMP kinase, thus linking 
vitamin D production to regulation other than that of UVB exposure.
•  The metabolism of vitamin D to 25OHD by the main 25-hydroxylase CYP2R1 is regulated by metabolic 
conditions, including obesity.
•  CYP3A4 like CYP24A1 metabolizes 25OHD and 1,25(OH)2D in both the 23 and 24 positions and may play a 
major role in vitamin D catabolism in the liver and intestines. Drugs like rifampin that induce CYP3A4 can 
lead to osteomalacia.
•  CYP27B1 regulation differs in different tissues because of differences in access of regulatory factors to en-
hancer modules in the CYP27B1 gene secondary to differences in chromatin organization.
•  Mice lacking Cyp27b1 if given enough 25OHD will normalize their 1,25(OH)2D levels, suggesting other 
enzymes with 1α-hydroxylase activity.
•  Tissue specificity in vitamin D function relates to differences in the regulation of VDR levels within different 
tissues and the tissue specific array of ancillary transcription factors and coregulators.
•  The “non genomic” 1,25(OH)2D binding protein variably known as MARRS/ERp57/PIA3 when deleted is 
embryonic lethal, but when deleted specifically in chondrocytes or in heterozygotes results in an abnormal 
growth plate and decreased bone formation that reverses after puberty.
•  Vitamin D sufficiency may be better characterized by measuring both the total and free concentrations of 
25OHD.
•  Large randomized clinical studies of subjects with normal vitamin D at baseline have shown little benefit 
from vitamin D supplementation.
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role of these enzymes in a number of clinical conditions. New discoveries into the regula-
tion of these enzymes has shown important links between metabolic conditions and vitamin 
D metabolism. Better understanding of how the VDR interacts with other transcription 
factors in a cell-specific fashion provides greater understanding of how the same molecule 
can have such different actions in so many physiologic processes. New and better methods of 
measuring the vitamin D metabolites and an understanding of the role of DBP in regulating 
the total and free levels of these metabolites provides us a greater appreciation of what 
constitutes vitamin D sufficiency and the difficulties in reaching consensus of such. Total 
25OHD levels may not be the best index of vitamin D sufficiency, and the level optimal for 
one group or one outcome may not be optimal for other groups or outcomes. It is not sur-
prising then that recommended levels for vitamin D intake and optimal levels of circulating 
25OHD levels vary somewhat from country to country and group to group. Clinical trials to 
address some of these questions have shown that vitamin D supplementation of individuals 
with normal 25OHD levels on average has a limited impact—at least over the short dura-
tion of the trials—on a number of nonskeletal conditions, but subpopulations such as the 
nonobese and those with low baseline levels of 25OHD may benefit. The answers are not all 
in, but the strides over the last few years have answered some of these questions, though 
they have also opened more.
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